ACTRN12605000363684已完成3 期
acetyl cysteine in Schizophrenia:A double blind randomised placebo controlled trial investigating a range of psychiatric rating scales
Stanley Medical Research Institute0 个研究点目标入组 150 人开始时间: 2005年9月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •DSM-IV diagnosis of schizophrenia, have a PANSS score of >55 or at least two items in the positive and/or negative items being >3 AND/OR have a CGI-S >3, be utilising effective contraception if of child-bearing age.
排除标准
- •Taking mood stabilisers, asthma or history of respiratory insufficiency/allergy to n-acetyl cysteine, abnormal heamotological findings, or systemic medical disorder, currently taking either 500mg of NAC/day, 200ug of selenium/day or 500 IU of Vitamin E/day or inability to comply with the informed consent.
研究者
相似试验
终止
4 期
Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative SymptomsACTRN12615001273572The University of Melbourne85
招募中
不适用
Effects of NAC on Symptoms of CHR PatientsProdromal SchizophreniaNCT05142735Centre for Addiction and Mental Health90
终止
不适用
An Open Trial of Cysteamine Treatment in SchizophreniaSchizoaffectiveSchizophreniaNCT01139125Augusta University3
终止
3 期
Augmentation of antipsychotic medication with anticonvulsant in the management of treatment resistant schizophreniaMental and Behavioural DisordersSchizophreniaISRCTN77257074King's College London371
Unknown
不适用
Neuroendocrine and Metabolite Substrates in SchizophreniaSchizophreniaNCT02423096Chang Gung Memorial Hospital200